MSB 0011359C

Drug Profile

MSB 0011359C

Alternative Names: M-7824; MSB0011359C

Latest Information Update: 13 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EMD Serono
  • Developer EMD Serono; M. D. Anderson Cancer Center; National Cancer Institute (USA)
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Programmed cell death-1 ligand-1inhibitors; Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer; Solid tumours
  • Phase I/II Colorectal cancer; Pancreatic cancer
  • Phase I Breast cancer

Most Recent Events

  • 13 Jun 2018 National Cancer Institute plans a phase I/II trial for Small Cell Lung Cancers (Second-line therapy or greater) in USA, in July 2018 , (NCT03554473)
  • 04 Jun 2018 Adverse events data from a phase I trial in Solid tumours presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 04 Jun 2018 Updated efficacy and adverse events data from a phase II trial in Solid tumours presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top